This board has been migrated to our new platform! Check out the new home page at discussion.fool.com or click below to go directly to the new Board on the new site.
Stock price is going down.It has lost half its value in the last year. I am expecting another 50% haircut in the next 3-4 months.In order to get the thesis you need to go into hospitals and see which drugs they are using. This guy got it imo.Argus Downgrades United Therapeutics To Hold, Cites 'Challenging Outlook'Last update: 24/05/2016 6:08:13 amUnited Therapeutics Corporation (NASDAQ: UTHR) reported its 1Q16 revenue and EPS short of consensus expectations. Argus’ Jacob Kilstein downgraded the rating for the company from Buy to Hold citing the challenging outlook.United Therapeutics reported its 1Q16 revenue at $369 million, up 13 percent y/y, but missing the consensus estimate of $397 million owing to disappointing sales of the company’s largest products. The company’s non-GAAP EPS came in at $3.02, up 18 percent y/y, but below the consensus forecast of $3.16.Reasons To Be WorriedAnalyst Jacob Kilstein enumerated the following reasons for the downgrade:Declining revenue for Remodulin and Tyvaso - Sales of Remodulin declined 4 percent y/y in 1Q to $140 million, while Tyvaso sales fell 10 percent to $102 million.Delayed FDA approval of a new implantable pump for RemodulinUnexpected resignation of two senior executives on the day of the earnings releaseStiff competition for Orenitram, a new oral version of Remodulin - Orenitram generated sales of $40 million in 1Q16, up 92 percent y/y. Management expects annual sales to eventually reach $1 billion. The analyst expressed concern, however, regarding competition from Actelion’s Uptravi. Launched in January 2016, Uptravi has seen “stronger and steadier prescription growth than Orenitram in its first months on the market.”Shares Fairly ValuedGiven the challenges being faced by United Therapeutics, shares seem to be fairly valued near $114, Kilstein said. He added, “Before returning the stock to our BUY list, we would need to see a clear strategy for overcoming the declining sales of Remodulin and Tyvaso and countering the competitive pressure on Orenitram.”
Best Of |
Favorites & Replies |
My Fool |